TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04752826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1808
Description: BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1808
Description: BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1808
Description: BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI-1808
Description: BI-1808, a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets TNFR2 administered at different dose \[Phase I, Part A\] and at Recommended Dose for Part B \[Phase I, Part B and Phase IIa\] by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Description: Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA® ) 25 Mg/mL Solution for Injection
Description: Pembrolizumab a programmed death receptor (PD-1) blocking antibody administered at 200mg by intravenous (IV) infusions every 3 weeks.
Study: NCT06533176

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personalized brain state-dependent single-pulse TMS
Description: Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized brain state-dependent single-pulse TMS
Description: Single-pulse TMS will be applied to the lesioned hemisphere during brain activity patterns associated with strong residual corticospinal tract activation and random brain activity patterns.
Study: NCT05751993

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADAPT
Description: The intervention is testing the feasibility of a reinforcement learning model to pull in participants' behavioral data (calories, activity, and weight) and use this data along with participants' past behavioral goal achievements to deliver the type of message that should be most effective for a given participant at a given time. At each decision point (morning, midday, and evening on a daily basis), the system evaluates which behaviors a participant is eligible to receive a message about (eating, activity, self-weighing), which intervention options a participant is eligible to receive, and then chooses what type of behavioral message a participant should receive. Over time, the model uses participant data and response to interventions to better tailor message choice.
Study: NCT05618561

Intervention type: DIAGNOSTIC_TEST
Intervention: EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test
Description: Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.

Intervention type: DIAGNOSTIC_TEST
Intervention: EuGeni SARS-CoV-2 Antigen Rapid Diagnostic Test
Description: Subjects have two swabs taken for analysis, one (combined or nasopharyngeal) with the kit under investigation and the other (by standard of care) for analysis with PCRl.
Study: NCT06080789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RABI-767
Description: 125 mg single-dose given by endoscopic-ultrasound (EUS) guided peripancreatic injection.
Study: NCT05428176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Undergo eHealth intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT06315335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB9741
Description: Pharmaceutical form: Solution Participants will receive UCB9741 during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pharmaceutical form: Solution Participants will receive Placebo during the Treatment Period.
Study: NCT06359080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognilum TM: Light Treatment Condition
Description: The children will wear the CognilumTM device for up to 15 minutes at a time, twice a week, for a period of 10 weeks.
Study: NCT06239103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field therapy
Description: Pulsed electromagnetic field therapy for 10 minutes, using a PEMF device, at 1 mT, 15 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Sham treatment, using the same PEMF device
Study: NCT04997525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Tablets
Description: Combined with progesterone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Combined with estradiol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin Alfa
Description: Combined with hCG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorionic Gonadotropin, Alpha
Description: In either natural cycle or combined with Follitropin Alfa
Study: NCT04467034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stanford Tobacco Prevention Toolkit curriculum
Description: Stanford Toolkit curriculum delivered as a 5-session course in a school classroom setting.
Study: NCT05529836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupunture
Description: The participants in EA group will receive acupuncture with PSD at bilateral Hegu (LI4), bilateral Quchi (LU5), bilateral Xuehai (SP10) and bilateral San Yinjiao (SP6). After skin disinfection, followed at an angle of 90°, acupuncture needles were inserted approximately 50 to 60 mm into the skin. When achieving qi, connect the four pairs of electrodes, two each on bilateral Quchi (LI4) and Hegu (LI11), two each on bilateral Xuehai (SP10) and San Yinjiao (SP6), and they are all ipsilateral to one another. The duration of the electroacupuncture stimulation is 30 minutes, and the current intensity ranges from 1 to 5 mA with a continuous wave of 20 Hz. For two weeks straight, the participants will have three therapy sessions each week (preferably every other day), for a total of six sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: Participants in the SEA group will receive sham electroacupuncture with PSD, but not energizing the electropuncture device. Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no electricity output only.
Study: NCT04997525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chorionic Gonadotropin, Alpha
Description: In either natural cycle or combined with Follitropin Alfa
Study: NCT05664412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: at-home tACS using Starstim-Home tES
Description: We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: at-home tACS using Starstim-Home tES
Description: We will use transcranial alternating current stimulation (tACS) of the dorsolateral prefrontal cortex and temporal cortex by adopting a high-density (HD) montage with 3 electrodes to target the dorsolateral prefrontal cortex and 3 electrodes to target the temporal cortex. To select individualized parameters for stimulation, we will first acquire and analyse structural MRI (comprising T1 and T2-weighted sequences) and EEG data during a working memory task. We planned one session of HD-tACS per day for 5 consecutive days every week over four weeks; each session will last 21 minutes. All sessions will occur during cognitive training (i.e., execution of a working memory task).
Study: NCT06237335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT2100
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCT2100
Description: RCT2100 supplied as varying dose strengths administered via oral inhalation using nebulizer

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of similar volumes to experimental dose strengths administered via oral inhalation using nebulizer
Study: NCT05529836

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham acupuncture
Description: Participants in the SAC group will receive sham acupuncture with PSD and PSN on sham acupoints (the non-meridian and non-acupuncture points). Procedures, electrode placements, and other treatment settings are the same as in the EA group but with no skin penetration, electricity output, or needle manipulation for achieving qi.
Study: NCT06025981

Intervention type: OTHER
Group type: OTHER
Intervention: Preliminary Phase
Description: In the preliminary phase, the characterization of the functionality of the SWalker robotic system, as well as the functionality of the Virtual Reality system, will be carried out. All descriptive usability questionnaires completed by the participants and electro-biomechanical parameters will be collected using the robot's measurement systems to analyze the functionality.

Intervention type: OTHER
Group type: OTHER
Intervention: Phase I - Early gait rehabilitation
Description: In the first phase, the participants will carry out the rehabilitation program for hip fracture in acute phase that will last 6 weeks. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the usual rehabilitation guidelines that integrate exercises aimed at improving strength, gait, functional mobility and balance. In the case of the experimental group, a robotic walker will be used to practice walking.

Intervention type: OTHER
Group type: OTHER
Intervention: Phase II - Maintenance gait function ( with VR)
Description: In the second phase, participants will carry out a 6-week program to consolidate walking function. Participants will be randomized between control and experimental groups. In which the therapeutic intervention is based on the use of the robotic system for gait exercise. In the case of the experimental group, the use of virtual reality will also be integrated.
Study: NCT06332495

Intervention type: OTHER
Intervention: Questioning the patient during hygiene care
Description: The study examines how patients and caregivers feel when using the bedpan. Over the course of a day, collecting all this information would take just under 7 minutes. Over the duration of patient participation (2 days), we estimate that it would take a total of 15 minutes per patient to collect this information. The objectives are focused on pain and discomfort, and on the alteration of the (patient's) skin condition through objective observation of redness or stage I pressure sores by the caregiver.
Study: NCT05248347

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy training simulator LM-092 (Koken Co., Ltd, Tokyo, Japan)
Description: Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BRONCH Mentor (Simbionix, GI-Bronch Mentor, USA)
Description: Participants who passed the theory test and was enrolled in this group will use this device to practice. After the appropriate time of practice, the test will be taken to evaluate the efficacy.
Study: NCT06511765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine and dexamethasone injection solution
Description: Injection of Ropivacaine and dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9% Injection Solution
Description: Injection of sodium chloride 0.9%
Study: NCT06512792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine management through Mobile APP
Description: According to the patient's electronic health records, each participating center researcher conducts personalized medication reminders and follow-up reminders for enrolled patients on a one-on-one basis. Simultaneously, patients are advised to monitor their health at home, regularly record and upload changes in clinical symptoms, medication, diet, exercise, etc., on the Mobile APP platform. Periodically, self-assessment scales are distributed through the Questionnaire Star platform to assess and record the patient's disease activity, quality of life, sleep, psychological status, etc., and update the information in the electronic health records.Based on the patient's clinical symptoms, self-assessment scales, and feedback from medical institution tests and examinations, each participating center researcher will promptly assess potential health risks, send warning alerts, and provide targeted informational support and interventions.
Study: NCT06486714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: All patients indicated for primary total knee arthroplasty will receive a cruciate-retaining cemented or cementless implant system, utilizing either MA or KA methodology.
Study: NCT05323708

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bmab 1000
Description: 60mg/ml Prefilled syringe single dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: 60mg/ml Prefilled syringe single dose
Study: NCT06335017

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor
Description: In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Induction of labor
Description: In both groups the balloon catheter will be removed at nearly 12 hours after insertion. Following removal, artificial rupture of the membranes will be performed as long as it is safe with regards to fetal head position. Oxytocin infusion will be commenced at once if contraction has not begun spontaneously (2 to 3 regular uterine contractions per 10 minutes). Continuous electronic fetal monitoring will be used throughout labor. Labor will be managed by the attending obstetricians and midwives. Labor progress abnormalities will be diagnosed and managed according to the department protocol based on the recommendations of the American College of Obstetricians and Gynecologists.
Study: NCT04998981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 0.1 mg tablet
Description: K-877 0.1 mg tablet x 2 twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate 200 mg capsule
Description: Fenofibrate 200 mg capsule once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet x 2 twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet x 2 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877 0.1 mg tablet
Description: K-877 0.1 mg tablet twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet twice daily
Study: NCT06583525

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Transition Support
Description: A multidisciplinary transition team (nurse practitioner and social worker) will coordinate the transition process for each patient across multiple settings, focused on the youth's highest priority needs while also supporting the caregivers. Participants will receive case management and care navigation using an intensive transition support model provided through the partnership of a transition team. The transition team will collaborate with the participants existing care team to help coordinate care, provide consultation, and support adult and primary care accepting these youth for 1 year following the transfer. This Intervention is modelled on best practices by Health Quality Ontario's Quality Standards for Transition from Youth to Adult Health Care Services to support youth at high risk of having poor transitional outcomes as they move from pediatric to adult care.
Study: NCT05639530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI333
Description: Intravitreal injection of IBI333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI333
Description: Intravitreal injection of IBI333
Study: NCT06583707

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling with and without ultrasound guidance
Description: The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling with and without ultrasound guidance
Description: The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dry needling with and without ultrasound guidance
Description: The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling with and without ultrasound guidance
Description: The dry needling technique involves inserting a sterile needle to stimulate a myofascial trigger point with the aim of reducing pain and increasing range of motion and quality of life. This technique can be performed using ultrasound guidance, which allows us to visualize the needle at all times, but it can also be done using anatomical landmarks. In the placebo dry needling technique, the needle will remain stationary in the subcutaneous tissue.